MyFinsight
Home
Blog
About
Back
Cash Flow
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)
source: myfinsight.com
Proceeds from issuance of
common shares
$3,499,991
(-53.32%↓ Y/Y)
Net cash provided by
financing activities
$3,446,937
(-79.54%↓ Y/Y)
Canceled cashflow
$53,054
Net change in cash
and cash...
$328,837
(-97.10%↓ Y/Y)
Canceled cashflow
$3,118,100
Payments for issuance
costs of common...
$53,054
(-82.01%↓ Y/Y)
Accounts payable and
accrued liabilities
$1,793,284
(260.41%↑ Y/Y)
Share-based compensation
$547,463
(68.34%↑ Y/Y)
Depreciation and
amortization
$25,644
(-72.55%↓ Y/Y)
Net cash used in
operating activities
-$3,082,673
(44.96%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$35,427
(-143.62%↓ Y/Y)
Canceled cashflow
$2,366,391
Net loss
-$5,407,611
(-9.09%↓ Y/Y)
Prepaid expenses and
other current assets
$25,313
(134.51%↑ Y/Y)
Accounts and other
receivable
$16,140
(-11.12%↓ Y/Y)
Back